Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 18/20 | 0.61 |
| ▸ | CHRNB2 | P17787 | 6/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 6/20 | 0.43 |
| ▸ | HTR3A | P46098 | 3/20 | 0.43 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.43 |
| ▸ | HTR3B | O95264 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.43 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.43 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6755095 | 1.00 | CHRNA7 (0.61) | CHRNA7CHRNB2CHRNA4HTR3AHTR3E | |
| SCHEMBL6628931 | 0.91 | CHRNA7 (0.51) | CHRNA7CHRNB2CHRNA4HTR3AHTR3E | |
| SCHEMBL6757496 | 0.91 | CHRNA7 (0.51) | CHRNA7CHRNB2CHRNA4HTR3AHTR3E | |
| SCHEMBL6758500 | 0.87 | CHRNA7 (0.47) | CHRNA7CHRNB2CHRNA4HTR3AHTR3E | |
| SCHEMBL6652599 | 0.87 | CHRNA7 (0.47) | CHRNA7CHRNB2CHRNA4HTR3AHTR3E | |
| SCHEMBL6758226 | 0.86 | CHRNA7 (0.46) | CHRNA7CHRNB2CHRNA4HTR3AHTR3E | |
| SCHEMBL6759418 | 0.85 | CHRNA7 (0.46) | CHRNA7CHRNB2CHRNA4HTR3AHTR3E | |
| SCHEMBL6802970 | 0.83 | CHRNA7 (0.62) | CHRNA7HTR3AHTR3EHTR3BCYP2D6 | |
| SCHEMBL5917958 | 0.83 | CHRNA7 (0.62) | CHRNA7HTR3AHTR3EHTR3BCYP2D6 | |
| SCHEMBL6630638 | 0.83 | CHRNA7 (0.62) | CHRNA7HTR3AHTR3EHTR3BCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040157878-A1 | Compounds as radioligands for the diagnosis of disease | PHARMACIA & UPJOHN COMPANY | 2004-08-12 | — | — | US | claimed |
| WO-2004052889-A1 | COMPOUNDS AS RADIOLIGANDS FOR THE DIAGNOSIS OF DISEASE | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-06-24 | — | — | WO | claimed |
| US-20040157878-A1 | Compounds as radioligands for the diagnosis of disease | PHARMACIA & UPJOHN COMPANY | 2004-08-12 | — | — | US | disclosed |
| WO-2004052889-A1 | COMPOUNDS AS RADIOLIGANDS FOR THE DIAGNOSIS OF DISEASE | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157878-A1 | Compounds as radioligands for the diagnosis of disease | CHRNG, CHRNB1, CHRNE | CHRNA7 14/4885CHRNB2 8/4885CHRNA4 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.